A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266 in Hypertensive Men (MK-8266-002)

• Status: Completed
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: Male

Summary

This study evaluated adverse events (AEs), study discontinuation due to AEs, and pharmacodynamics of MK-8266 in male participants with mild to moderate hypertension.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• Participant is male with essential hypertension (high blood pressure)

• Participant is in good general health (with the exception of hypertension)

• Participant has a Body Mass Index (BMI) <= 33 kg/m^2 at the Screening visit

• Participant has a platelet count >= 150,000 cu/mL at the Screening visit

• Participant has a positive AIx at the Screening visit

Exclusion Criteria:

• Participant has a history of stroke, chronic seizure, or major neurological disease

• Participant has a functional disability that can interfere with rising from a seated position to the standing position

• Participant has any history of a bleeding or clotting disorder

• Participant has a history of cancer

• Participant is unable to refrain from or anticipates the use of any prescription or non-prescription medication

• Participant consumes excessive amounts of alcohol or caffeinated beverages daily